Welcome to our dedicated page for Danaher Corporation SEC filings (Ticker: DHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Danaher Corporation (NYSE: DHR) SEC filings page provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings include current reports on Form 8‑K, quarterly reports on Form 10‑Q and other disclosures that detail Danaher’s financial performance, governance changes and capital markets activities as a global life sciences and diagnostics innovator.
Danaher uses Form 8‑K filings to report material events such as quarterly and annual financial results, estimated financial performance ahead of investor conferences, amendments to its by‑laws, share repurchase authorizations and changes in senior leadership or board composition. For example, the company has filed 8‑Ks to furnish earnings press releases and presentation slides, to describe updates to its by‑laws regarding shareholder proposal and nomination procedures, and to outline a share repurchase program authorizing the repurchase of up to 35 million shares of common stock.
The filings also list Danaher’s securities registered under Section 12(b) of the Exchange Act, including its common stock and multiple series of senior notes with various maturities, all traded on the New York Stock Exchange. This information helps investors understand the company’s capital structure and the instruments available in public markets.
Through its periodic reports, Danaher provides detailed financial statements, management’s discussion and analysis, and explanations of non‑GAAP measures such as core sales growth and adjusted diluted net earnings per common share. The company explains how it calculates these measures, why management uses them and how they reconcile to the most directly comparable GAAP figures, including adjustments for amortization of acquisition‑related intangible assets, fair value gains and losses on investments, impairments and tax effects.
On Stock Titan, users can review these SEC filings alongside AI‑powered summaries that highlight key points, such as revenue trends, margin drivers, capital allocation decisions, governance changes and risk disclosures. The platform’s tools can help readers quickly understand the implications of Danaher’s 10‑Q and 10‑K reports, as well as 8‑K items related to dividends, share repurchases, executive transitions and by‑law amendments, while still allowing detailed review of the original documents.
Danaher Corporation reported a routine compensation transaction for chairman of the executive committee Mitchell P. Rales. On
These notional shares track Danaher common stock on a one-for-one basis and are part of the company’s annual contribution to its deferred compensation programs. After this contribution, Rales holds a total of 8,048.204 notional units in the Danaher deferred contribution stock fund, which vest over time under the plan’s matching and non-elective contribution rules.
The Vanguard Group has filed an amended Schedule 13G/A reporting its ownership in Danaher Corp common stock as of 12/31/2025. Vanguard reports beneficial ownership of 60,973,344 shares, representing 8.63% of Danaher’s outstanding common stock.
Vanguard reports no sole voting or dispositive power over Danaher shares, with 6,222,423 shares subject to shared voting power and 60,973,344 shares subject to shared dispositive power. Vanguard states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Danaher. The filing notes an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries or business divisions may report beneficial ownership on a disaggregated basis.
Danaher Corporation furnished a current report to share its latest financial performance. On January 28, 2026, the company issued a press release detailing results for the year ended December 31, 2025, including fourth quarter performance, and attached this release as Exhibit 99.1.
The information was furnished under Item 2.02 and is expressly stated as not being deemed “filed” for liability purposes or automatically incorporated into other securities law filings, unless specifically referenced in a future document.
Danaher Corporation is providing an early look at its financial performance, sharing estimated results for the fourth quarter of 2025 and for full-year 2025. On January 12, 2026, the company issued a press release and presentation slides in connection with a public webcast at the J.P. Morgan Healthcare Conference on January 13, 2026. These materials, furnished under a current report, outline management’s view of recent performance and are incorporated by reference as exhibits, but are expressly designated as furnished rather than filed under securities law.
Danaher Corporation director and executive Mitchell P. Rales increased his deferred stock-based holdings through a plan contribution. On 12/30/2025, he acquired 1,543.981 derivative interests tied to Danaher common stock through the Danaher Deferred Compensation Plan’s Danaher Stock Fund.
The contribution is recorded as notional shares that track Danaher common stock on a one-for-one basis, with an exercise price of $0.00 and a reference price of $230.67 per share. Following this transaction, Rales held 7,969.204 derivative securities linked to Danaher stock in this plan. All deferrals in this stock fund are described as immediately vested, meaning the economic rights tied to these notional shares are fully earned when contributed.
Danaher Corp. (DHR) director and officer Mitchell P. Rales reported selling common stock in the company. On November 25, 2025, a family trust for which he serves as trustee sold 35,899 shares at a weighted average price of $230.27 and 4,726 shares at a weighted average price of $231.19.
After these transactions, the Mitchell P. Rales Family Trust held 850,000 Danaher shares. Rales also has additional beneficial holdings, including 553,228 shares held directly, shares in a 401(k) plan, shares in custodial accounts for his daughter (for which he disclaims beneficial ownership), and 25,671,000 shares held through single-member LLCs owned by a revocable trust of which he is sole trustee and beneficiary.
Danaher (DHR)Mitchell P. Rales filed a Rule 144 notice covering the planned sale of 40,625 shares of common stock through broker Monness, Crespi, Hardt & Co., Inc. on or about 11/25/2025, with an aggregate market value of $9,221,063. The filing notes that 706,349,563 shares of Danaher common stock were outstanding for context and that the shares are listed on the NYSE.
The securities to be sold were originally acquired on 06/11/2021 as part of a distribution from closely held Capital Yield Corporation, totaling 1,900,000 shares, with no cash payment due to the liquidation of that corporation. Over the past three months, Rales has already sold 600,000 shares of Danaher common stock on 10/31/2025 for gross proceeds of $129,635,820 and a further 437,000 shares on 11/12/2025 for gross proceeds of $95,566,167.
By signing the notice, the seller represents that he is not aware of any undisclosed material adverse information about Danaher’s current or prospective operations.
Danaher Corporation has a notice for the potential sale of 146,957 shares of common stock through broker Monness, Crespi, Hardt & Co., Inc. on the NYSE. The shares have an indicated aggregate market value of $33,356,300 based on the information provided, with 706,349,563 shares outstanding of this class. The approximate sale date listed is 11/25/2025.
The shares to be sold were acquired as common stock via a gift from affiliate Mitchell P. Rales on 06/11/2021, with the donor’s original acquisition date of 12/16/1983. The consideration is described as "None - gift to foundation", indicating the securities were transferred to a foundation rather than purchased for cash.
Danaher Corporation (DHR) director and officer Mitchell P. Rales reported an insider transaction involving Danaher common stock. On 11/25/2025, a family trust for which he serves as trustee transferred 22,029 shares of common stock as a gift at a reported price of $0. Following this transaction, that family trust held 890,625 shares indirectly.
In addition, Rales is shown as holding 553,228 shares directly, 667 shares through a 401(k) plan, and 3,256 shares in custodial accounts for his daughter, for which he disclaims beneficial ownership. A further 25,671,000 shares are held indirectly through single-member LLCs owned by a revocable trust of which he is sole trustee and beneficiary.
Danaher Corporation director Form 4 filing reports an option exercise and share sale. On 11/18/2025, a director exercised a stock option for 3,298 shares of Danaher common stock at an exercise price of $71.88 per share. That same day, the director sold 3,298 shares of common stock at a price of $226.50 per share. After these transactions, the director beneficially owned 20,761.994 shares of Danaher common stock held directly.